Erythropoietin single nucleotide polymorphisms are associated with anemia and 1 2 dyslipidemia in a cardiovascular disease population. Victoria Northrup<sup>1,2,6</sup>, Ashley L. Eadie<sup>1,2,6</sup>, Victoria L. Nelson<sup>1,2,6</sup>, Kenneth D'Souza<sup>1,2,3,6</sup>, Ansar 3 Hassan<sup>3,6</sup>, Thomas Pulinilkunnil<sup>2,4,6</sup>, Petra Kienesberger<sup>2,4,6</sup>, Jean-François Légaré<sup>3,6</sup>, Jeremy A. 4 Simpson<sup>5,6</sup>, Keith R. Brunt<sup>1,2,3,6</sup> 5 6 <sup>1</sup>Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada <sup>2</sup>Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada 7 8 <sup>3</sup>Departments of Cardiology & Cardiac Surgery, New Brunswick Heart Center, 9 Saint John Regional Hospital, Saint John, New Brunswick, Canada 10 <sup>4</sup>Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova 11 Scotia, Canada 12 <sup>5</sup>Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario, 13 Canada 14 <sup>6</sup>IMPART investigator team Canada (https://impart.team/) 15 Corresponding Author: 16 Dr. Keith R. Brunt 17 100 Tucker Park Road, Box 5050 18 19 Saint John, NB, Canada, E2L 4L5 20 1-(506)-636-6974 21 keith.brunt@dal.ca 22 @prof\_brunt (social media) 23 24 25

**Abstract** 

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Human erythropoietin (EPO) is an essential erythropoietic cytokine and recombinant biological therapeutic in anemia in chronic kidney disease. Single nucleotide polymorphisms (SNPs) in EPO have been linked to anemia and diabetic microvascular complications but no other cardiovascular comorbidities like dyslipidemia or hypertension. Here identified a clinical cohort of cardiovascular patients with anemia, dyslipidemia, hypertension, type-2 diabetes, or heart failure with preserved ejection fraction. Sanger sequencing was used for genotyping three EPO SNPs (rs1617640, rs507392 and rs551238), which were compared to clinical outcomes with SNPstat and clinical parameters profiles by student t-test. Nonstandard clinical chemistry measures of plasma EPO, hepcidin, transferrin, and ferritin were determined by ELISA. In the additive model, the C allele of rs1617640 was associated with lower EPO and anemia. In the recessive model, the SNP rs507392 genotype of GG was associated with dyslipidemia, which was associated with lower EPO in plasma and elevated total cholesterol and low-density lipoproteins. Interestingly, the G allele of rs507392 was found to be associated with hypertension, but only in females. Here we show that the SNPs in EPO are a potential risk factor for anemia, dyslipidemia, and hypertension in cardiovascular disease patients.

## Introduction

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Cardiovascular disease is one of the leading causes of death worldwide[1], with multiple contributing risk factors like anemia, including some linked to erythropoietin (EPO) or the use of erythropoietic stimulating agents.[2] Heart failure with preserved ejection fraction (HFpEF), is an especially challenging multimorbid condition featuring anemia, hypertension, type-2 diabetes mellitus (T2DM), obesity, or chronic kidney disease. The underlying cause of HFpEF and optimal medical management remains a challenge[1]. Microvascular complications are typically reported in HFpEF[3], and anemia in heart failure is generally associated with higher mortality, [4] severity, and hospital admission rates [5,6]. HFpEF is also more common in females, particularly those who are older, obese, and with a higher New York Heart Association (NYHA) classification. Microvascular complications in diabetes and anemia have been linked to EPO but have not previously been investigated in HFpEF or its multimorbid feature comorbidities. EPO is a master regulator of hematopoiesis and erythropoiesis, with secondary roles in cytoprotection and cellular metabolism.[7] Research on EPO has been extensive, yet clinical variation in EPO expression in health and disease and the underlying secondary mechanisms are poorly understood. A significant source of clinical variation in hormones like EPO can occur with haplotypes or single nucleotide polymorphisms (SNP). The entire gene of EPO has been known for decades, yet just three SNP have been identified as clinically relevant rs1617640(promoter), rs507392(intron) and rs551238(downstream). Genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) analysis have previously established that promoter SNP (rs1617640) is associated with an alteration in serum EPO,[8] a finding confirmed in healthy blood donors[9]. The promoter SNP (rs1617640) has also been

linked to diabetic microvascular complications [10–18], anemia in T2DM[19], and renal dysfunction after cardiac surgery[20] (Supplemental Table 1). In intron 3, SNP rs507392 was linked to diabetic microvascular complications [10,12,13,21] and overall higher mortality in diabetics [9]. SNP rs551238 (downstream of EPO) has also been associated with microvascular complications[9,10,12–15,21,22] and higher hematocrit in healthy blood donors [9] (Supplemental Table 1). Together, this suggests a potential link between microvascular complications, hematocrit, and EPO SNPs. These EPO SNPs have also been associated with EPO serum levels[18]. In CKD, a decrease in EPO is associated with anemia[23], whereas in other forms of anemia, EPO can be increased up to 100-fold, suggesting insensitivity in molecular signaling.[24] Secondary risks to CVD might also be linked to EPO independent of anemia, especially classic risk factors of CVD. For example, dyslipidemia is a salient risk factor for CVD characterized by abnormal serum cholesterol levels, triglycerides and related lipoproteins[25]. In mice treated with recombinant EPO (rhEPO), triglyceride levels were decreased[26] and lipoprotein lipase (in lipogenesis) was elevated.[26,27] In humans, treatment with rhEPO is associated with lower triglyceride levels and cholesterol in end-stage renal failure.[28] Although anemia, dyslipidemia, T2DM, hypertension are risk factors for CVD and multimorbid features of HFpEF with evidence of being modifiable by rhEPO—only anemia has been linked to EPO SNPs to date.[19] Here, we hypothesize that three EPO SNPs rs1617640(promoter), rs507292(intron) and rs551238(downstream)—correlate with EPO plasma concentrations and are associated with either anemia, dyslipidemia, T2DM, hypertension and/or HFpEF in a clinical population requiring surgical interventions for CVD.

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

#### Methods

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

Genomic DNA extraction

Genomic DNA (gDNA) was isolated from the buffy coat of blood collected during the impact of Obesity on Postoperative Outcomes following cardiac Surgery (OPOS) study (http://clinicaltrials.gov/study/NCT0324891). The OPOS cohort consisted of participants aged 18-75 years old who underwent elective cardiac surgery at either the New Brunswick Heart Center in New Brunswick, Canada or the Maritime Heart Centre in Nova Scotia, Canada.[29] The OPOS study and related biomarker discovery was approved by the Horizon Health Network Research Ethics Board (#RS20142006: RS100835). The buffy coat was separated from blood, and gDNA was isolated using either DNAzol® reagent (GibcoBRL cat # 10503-027) or QIAamp® DNA blood mini (Qiagen cat # 51104) kits (following the manufacturer's protocol). DNA was quantified by spectroscopy on a BioTek Synergy TM H4 Hybrid Microplate reader using the 260:280 nm ratio by the Gen5 software (BioTek), and the average concentration of technical duplicates was used. Primer design Primers were designed using Oligo 7 software (Table 1).[30] Primers designed for gDNA sequencing included M13 sequences[31] to facilitate Sanger sequencing and M13 primers were used in sequencing reactions. Polymerase Chain Reaction End-point polymerase chain reaction (PCR) was performed on gDNA using AmpliTaq Gold<sup>™</sup> 360 Master Mix (Applied Biosystems cat # 4398881). PCR reactions consisted of 1 X AmpliTaq Gold<sup>TM</sup> 360 Master Mix, 0.3 µM of forward and reverse primers, 4 µg of Bovine Serum Albumin (BSA, Thermo Scientific), 50 ng of gDNA and nuclease-free water up to 15 μL.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

Reactions were amplified on a Mastercycler Nexus Gradient Thermocycler (Eppendorf) using the cycling conditions listed in Table 2. PCR products were verified using 7500 Agilent DNA Chips (Agilent cat # 5067-1506) on the Bioanalyzer 2100 system (Agilent). PCR products were cleaned up using 2 µL of ExoSAP-IT<sup>TM</sup> (Applied Biosystems cat # 78200) in 5 μL of PCR product and incubating at 37°C for 15 minutes. ExoSAP-IT<sup>TM</sup> was inactivated at 80°C for 15 minutes. Sanger Sequencing Sequencing reactions were prepared using a BigDye<sup>TM</sup> Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems cat# 4337457). The cleaned PCR product was added to a reaction of 1X Sequencing buffer, 1X BigDye<sup>TM</sup> MasterMix, and 2μM primer of M13 sequencing primers.[31] Sequencing reactions were incubated at 96°C for 1 minute and 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 60°C for 4 minutes. BigDye<sup>TM</sup> Xterminator beads (Applied Biosystems cat # 4376486) were added to the sequencing reaction and vortexed at 2000 rpm for 25 minutes. Samples were centrifuged for 2 minutes at 2000 X rcf and let rest for 2 minutes before centrifuging again at 2000 X rcf for 30 seconds, followed by another 30 seconds of rest to ensure that beads were sedimented. Then, 20µL of the sequencing reaction (without beads) was transferred to a 96-well plate and loaded onto the 3500 Genetic Analyzer (Applied Biosystems) for sequencing. Sanger Sequencing Analysis Sequences were analyzed using BioEdit Sequences Alignment Editor software.[32] The forward and reverse sequences were aligned using the ClustalW Multiple alignment tool to generate the consensus sequence for each product. Sequences were submitted to NCBI Blast to validate correct target amplification and were compared to the NCBI reference sequence

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

NG 021471.2 to identify variants. A variant was defined as any base calling that differed from the reference sequence. SNP analysis SNPStats (www.snpstats.net)[33] was used to determine allele and genotype frequencies, test for Hardy-Weinberg equilibrium, assess SNP response using logistic regression in multiple inheritance models (co-dominant, dominant, recessive, over-dominant and log-additive), linkage disequilibrium statistics, and for haplotype analysis. Analysis used sex, age, and body mass index (BMI) as co-variants. A p-value < 0.05 was deemed significant. Clinical findings were obtained from the OPOS BioBank (storing retrievable databases of de-identified data abstracted from patient records). Comparisons of clinical values with genotype were performed using a student t-test to determine the p-value (<0.05 significant). A Kolmogorov-Smirnov test in GraphPad was used to confirm normality. A ROUT (Q=1) test in GraphPad was used to determine outliers; outliers were still presented and identified by encirclement in figures for clinical relevance but were otherwise excluded from group testing. Enzyme-linked immunosorbent assays Plasma samples collected from OPOS [29] were used for enzyme-linked immunosorbent assays (ELISA) for EPO (Human EPO ELISA kit, Invitrogen Cat # BMS2035-3), Transferrin (Transferrin Human ELISA Kit, Invitrogen cat # EHTF), Hepcidin (Human Hepcidin Quantikine ELISA kit, R&D systems cat # DHP350) and Ferritin (Ferritin Human ELISA Kit, Invitrogen cat # EHFTL). Plasma samples were diluted 1:2 for EPO, 1: 20,000 for Transferrin, 1:5 for Hepcidin, and 1:10 for Ferritin using the kit manufacturer's diluent. ELISAs were performed using the manufacturer's protocol and absorbance was measured at 450 nm using the Synergy H4 plate reader. GraphPad Prism (Prism9) was used for statistical analysis and graphing data.

Two-way ANOVA was used to determine p-values. A p-value of <0.05 was deemed significant.

## **Results**

## Subcohort of patients with multimorbid conditions at elevated risk of CVD

The OPOS sub-cohort analyzed herein consisted of 95 participants recruited for the OPOS study (358 participants). Participants with at least one condition: anemia, dyslipidemia, hypertension, T2DM and/or diagnosed HFpEF, were sampled as a sub-cohort. The demographics and clinical parameters of the OPOS cohort are shown in Table 3 and Supplemental Table 2. Some multimorbid parameters overlap between controls and the cases in each condition but otherwise served provided sex and age matched controls with CVD but without the specified outcome. Among these cases, dyslipidemia were associated with a higher NYHA score. BMI was higher in patients with T2DM and anemia but lower in those with HFpEF. Males were more prevalent in T2DM, hypertension, and dyslipidemia sub-populations. In contrast, females were more prevalent in anemia (taking into consideration the sex-dependent normal ranges used for males/females of the study population). Overall, this subcohort represents patients with salient risk factors requiring an intervention by cardiac surgery.

## Reassurance of experimental approach for avoiding SNP linkage disequilibrium

SNPs rs1617640(promoter), rs507392(intron) and rs551238(downstream) are located within 4.2 kb of one another. Due to this proximity, linkage disequilibrium is likely to occur[34]. Here, we performed a linkage disequilibrium analysis using SNPstats and found a high degree of linkage disequilibrium between our three SNPs (Supplemental Figure 1a). The highest degree of linkage disequilibrium was measured between rs1617640(promoter) and rs507392(intron), followed by rs507392(intron) and rs551238(downstream). SNPs rs1617640(promoter) and

rs551238(downstream) were observed to have the least degree of disequilibrium. These associations correlated with the SNPs' positions along the *EPO* gene, with those closest in proximity (Supplemental Figure 1b) showing the highest degree of disequilibrium.

## The presence of the C allele in rs1617640(promoter) increases the risk of anemia

Each SNP was examined for association based on dominant, recessive, or additive inheritance models (Table 4). The C allele of rs1617640 SNP in the promoter region was associated with anemia in an additive inheritance model with an odds ratio (OR) of 1.96 (p-value 0.04). Whether clinical parameters correlated with specific genotypes was then investigated. In SNP rs1617640, there were significant differences between genotypes in hemoglobin, neutrophil to lymphocyte ratios (NLR), cholesterol, low-density lipoprotein (LDL), and non-high-density lipoprotein (non-HDL) (Supplemental Table 3, Supplemental Figure 2). The lower hemoglobin levels in the CC genotype support the association of anemia with the C allele, with the higher NLR suggesting elevated inflammation. The rs1617640(promoter) CC genotype was associated with a lower plasma EPO level, although iron bioavailability (as measured by Ferritin, Hepcidin and Transferrin) was not significantly different (Figure 1). These findings suggest that SNP rs1617640(promoter) is likely affecting EPO directly, not through iron bioavailability.

# GG Genotype of rs507392(intron) is protective against dyslipidemia

To characterize the role of the GG Genotype of intron SNP (rs507392) we examined the OR-value for anemia, dyslipidemia, and hypertension. The GG genotype of rs507392 was associated with protection against dyslipidemia in a recessive model (OR value = 0.29; p-value = 0.048) (Table 4), while there was no significance with anemia or hypertension. Variations based

on genotype in rs507392(intron) were seen in clinical parameters including cholesterol, LDL, non-HDL, and NLR (Supplemental Table 4, Supplemental Figure 3). This suggests that SNP rs507392(intron) is associated with lipid handling/regulation. As with rs1617640(promoter), the GG genotype in rs507392(intron) demonstrated lower levels of EPO in the plasma (Figure 1). There was no association to risk factors for SNP rs551238(downstream) (Table 4), and fewer significant differences in clinical parameters were observed (Supplemental Table 5 and Supplemental Figure 4). Unlike rs1617640(promoter) and rs507392(intron), no significant EPO changes in rs551238(downstream) were observed (Figure 1).

## No strong evidence for EPO haplotype association with risk factors

Haplotype was also examined to determine the cumulative effects of all three SNPs to clinical outcomes. The predominant haplotypes of AAT and CGG did not correlate with any clinical phenotype. However, one of the rare haplotypes of CGT (which occurred in approximately 3% of our cohort) did correlate with dyslipidemia. The OR-value of 0.05 suggests that the CGT haplotype is protective against dyslipidemia but should be interpreted with caution given the low prevalence (Table 5, Supplemental Table 6).

## Sex differences are apparent with SNP associations to risk factors

Precision medicine necessitates accounting for sex differences, and here we find meaningful sex effects to the associated risk factors. In males, the prevalence of dyslipidemia, T2DM, and hypertension are significantly higher than that observed in females[35], whereas in females, the prevalence of anemia[36] and HFpEF[37] is significantly higher. Given these sex differences in the clinical phenotypes examined herein, we analyzed the differences in SNPs

within each sex to determine if sex differences would affect our results. SNP rs507392(intron) AG and GG genotypes, and rs551238(downstream) TG genotype, were associated with hypertension in females, but not in males (Table 6, Supplemental Table 7), suggesting that the rs507392(intron) and rs551238(downstream) SNPs could be risk factors for hypertension in females but not males.

# New EPO variants of potential concern identified

During the analysis of *a priori* sequences obtained for rs1617640(promoter), rs507392(intron), and rs551238(downstream), other variants were also identified (Supplemental Table 8). Many of these variants were only detected in a single individual as a heterozygote; others were identified in a several individuals, with most being heterozygotes. However, most of these variants have not previously been reported and are, therefore, of unknown significance. Three variants were found in a significant subset of our population, including a four-base pair deletion (2167?-2170?del). This variant is located within a repeat region in intron 3, and thus the breakpoint may be inexact. This base pair deletion was found to be homozygous in 76 cases and suspected to be heterozygous in 4 cases. The 3154T>G substitution was found in 83 individuals, with 77 of these determined as homozygotes. Lastly, 3806T>C was found in 33 individuals, with 31 of these determined as heterozygotes. This data suggests more variation in EPO than previously reported, which needs further exploration in larger study populations where further associations can be uncovered.

## **Discussion**

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

Here, we identified linkage between the three EPO SNPs and cardiovascular disease risk factors, including dyslipidemia and HFpEF-associated comorbidities: anemia, T2DM, and hypertension. The CC genotype of rs1617640(promoter) and GG genotype of rs507392(intron) were associated with lower EPO plasma levels and correlated with comparably higher cholesterol, LDL, and non-HDL lipoproteins. The promoter-SNP (rs1617640) CC was associated with lower Hb and anemia in a log additive model and has been previously linked to anemia in T2DM[19]. While the role of the promoter-SNP in CVD has been explored to a lesser extent, our data support it as being linked to anemia in CVD. Surprisingly, the intron-SNP (s507392) GG genotype had a protective association with dyslipidemia in a recessive model. There was no significant association between hypertension and the SNPs in the overall population, although rs507392(intron) and rs551238(downstream) were associated with hypertension in females, suggesting a sex dependence. Our study highlights that EPO variants are associated with comorbid conditions that present significant cardiovascular risk factors of anemia, dyslipidemia, and hypertension for the first time. EPO levels are well known to be associated with anemia [23,24], so any SNP that alters plasma EPO levels, such as rs1617640(promoter) and rs507392(intron), as we have shown, could be risk factors for anemia, and require additional pharmacogenetic guided intervention. Yet, iron bioavailability also contributes to two of the most common forms, iron-deficiency anemia and anemia of inflammation (or anemia of chronic disease, e.g., CVD)[38]. The rs1617640(promoter) C-allele associated with anemia was also associated with NLR, indicative of active inflammatory processes [39,40]. This suggests the C allele for rs1617640(promoter) is associated with inflammation and decreased Hb. It has been purported that EPO can exert an

indirect anti-oxidant effect by utilizing iron in erythrocytosis resulting in less bioavailable iron.[41] Patients with anemia of inflammation commonly have reduced serum iron and normal to elevated iron stores.[42] In blood, iron is transported by transferrin[43] and can be stored in ferritin within most cells, like macrophages and hepatocytes.[44] The release of recycled iron from intracellular stores is partially regulated by hepcidin—a hormone that inhibits the transportation of intracellular iron to the blood and is induced by inflammation.[38] Hypoxia-inducible factors (HIFs; which upregulate *EPO*[7]) also reduce hepcidin, thus increasing transferrin, ferritin, and iron bioavailability.[45] We measured hepcidin, transferrin and ferritin to examine whether the *EPO* SNPs altered iron bioavailability. Still, despite elevated NLR associated with allelic frequency, we did not find significant differences between genotypes. This leads us to conclude that the SNPs in *EPO* are likely not exerting their effects by regulating iron bioavailability.

Ours is the first study to identify *EPO* SNPs associated with dyslipidemia and/or lipoproteins in medically managed patients. Prior studies have reported that rhEPO therapy modulates triglycerides, cholesterol, and other lipoproteins [26–28]. In a mouse model of CKD, treatment with rhEPO resulted in decreased triglycerides, cholesterol and LDL, but not HDL[26]. In the present study, the GG genotype of rs507392(intron) correlated with lower EPO concentrations but increased cholesterol, LDL and non-HDL. These variations would also be expected with diagnosed dyslipidemia, yet the GG genotype was associated with resistance to dyslipidemia. This apparent contradiction is, however, more likely a consequence of medical management of dyslipidemia (e.g., statins) to lower lipoprotein levels[46], not the association to the clinical outcome. Future studies could be designed to validate this epidemiologically with sufficient covariant adjustments. While rs1617640(promoter) and rs551238(downstream) did not

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

associate with dyslipidemia as an outcome, there was significant variation in cholesterol, with the rs1617640(promoter)AC variant genotype being significantly lower for LDL and non-HDL lipoproteins. The rs551238(downstream) TG variant was significantly associated with lower cholesterol and non-HDL. The CGT haplotype was found to be protective against dyslipidemia, but this was a rare finding (less than 3% of cohort) and should be interpreted with caution. Together, these results show that *EPO* SNPs influence lipid metabolism and that rs507392(intron) is associated with dyslipidemia. The fundamental biology and molecular biology of EPO in these processes need to be explored further.

Many clinical phenotypes, including those examined here, have sex differences attributable to prevalence, response to treatment, or clinical outcomes. Hypertension did not show an association with the SNPs with the sexes combined, yet the presence of the G allele in rs507392(intron) and the TG genotype in rs551238(downstream) showed an elevated risk in females but not males. Hypertension is more prevalent in males[35], and our cohort contained more males than females, which might explain why this association was initially masked. The relationship between estrogen and the renin-angiotensin-aldosterone system (RAAS) is thought to be one of the main reasons for the sex differences observed in hypertension. The RAAS has also been found to be modulated by EPO: in Wistar rats, rhEPO increases renin[47] and in isolated rat kidneys, rhEPO promotes angiotensin II (AngII) production. [48] In the oviduct and endometrium, estrogen (17 $\beta$  (E2)) can also promote the expression of EPO.[49,50] Given the relationship between EPO and the RAAS system by estrogen, this could be a potential mechanism for why the G allele of rs507392 and TG genotype of rs551238 are risk factors for hypertension just in females. Although this finding does require validation in a larger cohort (including more females with a direct assessment of sex hormones), this may be a significant

finding since hypertension tends to be a more salient risk factor for CVD in females.[51]

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

Our results suggest that EPO SNPs may be associated with risk factors and comorbidities of CVD by affecting the amount of EPO produced. Given the ability to modulate the amount of EPO either directly through rhEPO or indirectly by targeting upstream of EPO using hypoxia-inducible factor prolyl-hydroxylase inhibitors, these SNPs could be used to inform the best course of medical management. Hypoxia-inducible factor (HIF) prolyl-hydroxylase inhibitors increase EPO by stabilizing the HIFs that transcriptionally act upon EPO DNA under normoxic conditions.[52,53] Though not yet established, should EPO SNP result in less HIF binding to EPO in transcriptional regulation or stability of the intronic stores of EPO mRNA[54], then the use of HIF prolyl-hydroxylase inhibitors may be less potent for directly increasing EPO compared to rhEPO. Although more work is needed before these SNPs are applied clinically, they could guide pharmacogenetic interventions that seek to increase EPO or address anemia in the future or reclassify existing clinical trial data for subgroup analyses. In addition to the principally known SNPs, we also identified novel variants. Most occurred as heterozygotes in a single individual, but four occurred in multiple individuals and are potential polymorphisms. In clinical care, sequencing is more commonplace because of the integration of next-generation sequencing technologies into standard care. In other disorders, this led to increased variant detection.[55] Surprisingly, EPO has long been overlooked on many gene arrays or panels, which may account for the low prevalence of EPO variants in the literature. As the sequencing of EPO increases, we anticipate further variants of concern can be detected, with a potential for linkages in large epidemiology studies now that we have discovered them. Our study is not without limitations. One was the small sample size and depth of patient

file analyses, which did not allow us to account for many covariates (such as ethnicity, other

comorbidities, or medical management) that could affect our results. Our study did identify dyslipidemia as a novel disorder and can direct further focused sequencing toward cases of dyslipidemia and potentially investigate use/efficacy of statins as a covariant. Additionally, hypertension was identified in females but not males, with the rs507392 G allele and rs551238 TG genotype being risk factors. As we had relatively few females, more sequencing should target females with hypertension. Even with our sample size, we have identified variables that can benefit epidemiological or database studies to validate clinical relevance, screening risk or precision medical management.

Here, we have established that *EPO* SNP rs1617640 C-allele was associated with anemia, as well as changes in lipid metabolism and inflammation. We show the association of GG genotype for rs507392 to dyslipidemia for the first time. This genotype indicates effects on lipid profiles despite standard care. In females only, we show that the rs507392 and rs551238 *EPO* SNPs are associated with hypertension. Together, our results suggest that SNPs in *EPO* are involved in Hb regulation, lipid metabolism, and inflammation with a female-specific effect on blood pressure.

## Acknowledgements

Blood samples for gDNA and clinical data were obtained from the IMPART BioBank (https://impart.team/biobank/). Clinical data and samples were retrieved by IMPART BioBank staff, including Dr. Christie Aguiar, Angella Mercer, and Saumil Shah, in collaboration with the authors who extend their appreciation. The IMPART BioBank was supported by endowed funds from the Dalhousie Medical Research Foundation and specialized equipment provided by Saint John Regional Hospital Foundation-directed donation. This study was supported by the Natural

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

Sciences and Engineering Research Council (NSERC) [discovery grant #RGPIN-2018-05626 and #RGPIN-(2020)-04878] (JAS & KRB), Heart & Stroke Foundation of New Brunswick and the generosity of the Chesley Family Grant (KRB). VN was supported by the NSERC Alexander Graham Bell Canada Graduate Scholarship-Doctoral (CGS-D) and the New Brunswick Health Research Foundation Beatrice Hunter Cancer Research Training Program Award. **Authorship Contributions** Conceived; designed experimental approaches of the study (VN, JAS, KRB); Mentored trainee acquisition of data and execution of the study (JAS & KRB); Collected and assembled data for the study (VN, ALE, VLN, KD, AH, TP, PK, JFL, & KRB); Analyzed; interpreted & reported data (VN, AE, VLN, & KRB); Drafted manuscript (VN & KRB); critically reviewed, revised and edited manuscript for intellectual content and approved final work (VN, ALE, VLN, KD, JFL, JAS, & KRB). **Disclosure of Conflict of Interest** At the time of study and reporting, KRB declares equity holdings in Fibrogen Inc. and serves as director and majority shareholder in NBBM Inc.

380 381 References 382 Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev 1 383 2017;**03**:7. doi:10.15420/CFR.2016:25:2 384 Jean-Baptiste W, Yusuf Ali A, Inyang B, et al. Are There Any Cardioprotective Effects or 2 385 Safety Concerns of Erythropoietin in Patients With Myocardial Infarction? A Systematic 386 Review. Cureus 2022;14. doi:10.7759/CUREUS.25671 387 Bilak JM, Alam U, Miller CA, et al. Microvascular Dysfunction in Heart Failure with 3 388 Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. 389 Card Fail Rev 2022;8. doi:10.15420/CFR.2022.12 390 4 Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset 391 392 heart failure. Circulation 2003;107:223-5. doi:10.1161/01.CIR.0000052622.51963.FC 393 5 Silverberg DS, Wexler D, Blum M, et al. The cardio renal anemia syndrome: correcting 394 anemia in patients with resistant congestive heart failure can improve both cardiac and 395 renal function and reduce hospitalizations. Clin Nephrol 2003;60 Suppl 1:S93-102. 396 6 Caramelo C, Justo S, Gil P. Anemia in Heart Failure: Pathophysiology, Pathogenesis, 397 Treatment, and Incognitae. Rev Española Cardiol (English Ed 2007;60:848–60. 398 doi:10.1016/S1885-5857(08)60029-8 399 7 Bunn HF. Erythropoietin. Cold Spring Harb Perspect Med 2013;3:a011619. 400 doi:10.1101/cshperspect.a011619 401 8 Harlow CE, Gandawijaya J, Bamford RA, et al. Identification and single-base gene-402 editing functional validation of a cis-EPO variant as a genetic predictor for EPO-

403 increasing therapies Graphical abstract Authors. Published Online First: 2022. 404 doi:10.1016/j.ajhg.2022.08.004 405 Khabour OF, Bani-Ahmad MA, Hammash NM. Association between polymorphisms in 9 406 erythropoietin gene and upper limit haematocrit levels among regular blood donors. 407 Transfus Clin Biol 2012;19:353-7. doi:10.1016/J.TRACLI.2012.10.001 408 10 Abhary S, Burdon KP, Casson RJ, et al. Association between erythropoietin gene 409 polymorphisms and diabetic retinopathy. Arch Ophthalmol 2010;128:102–6. 410 doi:10.1001/archophthalmol.2009.355 411 11 Alwohhaib M, Alwaheeb S, Alyatama N, et al. Single nucleotide polymorphisms at 412 erythropoietin, superoxide dismutase 1, splicing factor, arginine/serin-rich 15 and 413 plasmacytoma variant translocation genes association with diabetic nephropathy. Saudi J 414 *Kidney Dis Transpl* 2014;**25**:577–81. doi:10.4103/1319-2442.132190 415 12 Fan YF, Fu YY, Chen Z, et al. Gene-gene interaction of erythropoietin gene 416 polymorphisms and diabetic retinopathy in Chinese Han. Exp Biol Med 2016;241:1524— 417 30. doi:10.1177/1535370216645210 418 13 Kaur N, Singh IR, Vanita V. Association of Erythropoietin Gene Polymorphisms With 419 Type 2 Diabetic Retinopathy in Adult Patients From Northern India. Can J Diabetes 420 2021;**45**:785–91. doi:10.1016/j.jcjd.2021.03.008 421 14 Li H, Xu H, Li Y, et al. Associations between erythropoietin polymorphisms and risk of 422 diabetic microvascular complications. *Oncotarget* 2017;8:112675–84. 423 doi:10.18632/oncotarget.22699 424 15 Liu C, Bai GL, Liu P, et al. Role of EPO and TCF7L2 Gene Polymorphism Contribution 425 to the Occurrence of Diabetic Retinopathy. Dis Markers 2022;2022:6900660.

426 doi:10.1155/2022/6900660 427 16 Mankoč Ramuš S, Pungeršek G, Petrovič MG, et al. The GG genotype of erythropoietin 428 rs 1617640 polymorphism affects the risk of proliferative diabetic retinopathy in Slovenian 429 subjects with type 2 diabetes mellitus: enemy or ally? Acta Ophthalmol 2021;99:e1382–9. 430 doi:10.1111/AOS.14813 431 17 Sesti LFC, Sbruzzi RC, Polina ER, et al. Association of polymorphisms in the 432 erythropoietin gene with diabetic retinopathy: a case—control study and systematic review 433 with meta-analysis. BMC Ophthalmol 2022;**22**:250. doi:10.1186/S12886-022-02467-Y 434 18 Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in 435 severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A 2008;105:6998— 436 7003. doi:10.1073/pnas.0800454105 437 19 Chiou TTY, Lee JJ, Wang MC, et al. Genetic disposition and modifiable factors 438 independently associated with anemia in patients with type 2 diabetes mellitus. Diabetes 439 Res Clin Pract 2015;108:164–9. doi:10.1016/j.diabres.2014.12.012 440 20 Popov AF, Schulz EG, Schmitto JD, et al. Relation between renal dysfunction requiring 441 renal replacement therapy and promoter polymorphism of the erythropoietin gene in 442 cardiac surgery. Artif Organs 2010;34:961–8. doi:10.1111/j.1525-1594.2010.01108.x 443 21 Song Q, Zhang Y, Wu Y, et al. Association of erythropoietin gene polymorphisms with 444 retinopathy in a Chinese cohort with type 2 diabetes mellitus. Clin Exp Ophthalmol 445 2015;**43**:544–9. doi:10.1111/ceo.12505 446 22 Sobrin L, Green T, Sim X, et al. Candidate gene association study for diabetic retinopathy 447 in persons with type 2 diabetes: The candidate gene association resource (CARe). *Investig* 448 Ophthalmol Vis Sci 2011;52:7593-602. doi:10.1167/IOVS.11-7510/-

449		/DCSUPPLEMENTAL
450	23	Portolés J, Martín L, Broseta JJ, et al. Anemia in Chronic Kidney Disease: From
451		Pathophysiology and Current Treatments, to Future Agents. Front Med 2021;8:642296.
452		doi:10.3389/FMED.2021.642296/BIBTEX
453	24	Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive
454		chemotactic effect on endothelial cells. Proc Natl Acad Sci 1990;87:5978-82.
455		doi:10.1073/PNAS.87.15.5978
456	25	Berberich AJ, Hegele RA. A Modern Approach to Dyslipidemia. Endocr Rev
457		2022; <b>43</b> :611–53. doi:10.1210/endrev/bnab037
458	26	Li J, Yang M, Yu Z, et al. Kidney-secreted erythropoietin lowers lipidemia via activating
459		JAK2-STAT5 signaling in adipose tissue. EBioMedicine 2019; <b>50</b> :317.
460		doi:10.1016/J.EBIOM.2019.11.007
461	27	Penna F, Busquets S, Toledo M, et al. Erythropoietin administration partially prevents
462		adipose tissue loss in experimental cancer cachexia models. J Lipid Res 2013;54:3045.
463		doi:10.1194/JLR.M038406
464	28	Pollock CA, Wyndham R, Collett P V., et al. Effects of erythropoietin therapy on the lipid
465		profile in end-stage renal failure. <i>Kidney Int</i> 1994; <b>45</b> :897–902. doi:10.1038/KI.1994.118
466	29	Aguiar C, Macleod J, Yip A, et al. Impact of Obesity on Postoperative Outcomes
467		following cardiac Surgery (The OPOS study): Rationale and design of an investigator-
468		initiated prospective study. BMJ Open 2019;9:e023418. doi:10.1136/bmjopen-2018-
469		023418
470	30	Rychlik W. OLIGO 7 Primer Analysis Software. Humana Press 2007. doi:10.1007/978-1-
471		59745-528-2_2/FIGURES/2_14_978-1-59745-528-2

472	31	Andersson B, Lu J, Edwards KE, et al. Method for 96-Well M13 DNA Template
473		Preparations for Large-Scale Sequencing. <i>Biotechniques</i> 1996; <b>20</b> :1022–7.
474		doi:10.2144/96206ST03
475	32	Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis
476		program for Windows 95/98/NT. Nucleic Acids Symp Ser 1999;41:95-8.
477	33	Solé X, Guinó E, Valls J, et al. SNPStats: a web tool for the analysis of association
478		studies. Bioinformatics 2006;22:1928–9. doi:10.1093/BIOINFORMATICS/BTL268
479	34	Reich DE, Cargill M, Bolk S, et al. Linkage disequilibrium in the human genome. Nature
480		2001; <b>411</b> :199–204. doi:10.1038/35075590
481	35	Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends
482		in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to
483		2016. Circulation 2019; <b>139</b> :1025–35. doi:10.1161/CIRCULATIONAHA.118.035550
484	36	Lionel AC, Waters R, Sholzberg M, et al. Sex Differences in Anemia and Red Blood Cell
485		Transfusions Among General Internal Medicine Inpatients. <i>Blood</i> 2021; <b>138</b> :1074–1074.
486		doi:10.1182/BLOOD-2021-154106
487	37	Sotomi Y, Hikoso S, Nakatani D, et al. Sex differences in heart failure with preserved
488		ejection fraction. J Am Heart Assoc 2021;10:1–20. doi:10.1161/JAHA.120.018574
489	38	Lanser L, Fuchs D, Kurz K, et al. Physiology and Inflammation Driven Pathophysiology
490		of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment.
491		Nutrients 2021;13:3732. doi:10.3390/NU13113732
492	39	Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives.
493		Bratislava Med J 2021; <b>122</b> :474–88. doi:10.4149/BLL_2021_078
494	40	Gawdat K, Legere S, Wong C, et al. Changes in Circulating Monocyte Subsets (CD16

495		Expression) and Neutrophil-to-Lymphocyte Ratio Observed in Patients Undergoing
496		Cardiac Surgery. Front Cardiovasc Med 2017;4:12. doi:10.3389/fcvm.2017.00012
497	41	Katavetin P, Tungsanga K, Eiam-Ong S, et al. Antioxidative effects of erythropoietin.
498		Kidney Int Suppl 2007;72. doi:10.1038/SJ.KI.5002482
499	42	Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011–23.
500		doi:10.1056/NEJMRA041809
501	43	Bomford AB, Munro HN. Transferrin and its receptor: their roles in cell function.
502		Hepatology 1985; <b>5</b> :870–5. doi:10.1002/HEP.1840050528
503	44	Nairz M, Theurl I, Swirski FK, et al. "Pumping iron"—how macrophages handle iron at
504		the systemic, microenvironmental, and cellular levels. <i>Pflugers Arch</i> 2017; <b>469</b> :397–418.
505		doi:10.1007/S00424-017-1944-8
506	45	Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors in iron
507		metabolism. Cell Cycle 2008;7:28–32. doi:10.4161/CC.7.1.5145
508	46	Zodda D, Giammona R, Schifilliti S. Treatment Strategy for Dyslipidemia in
509		Cardiovascular Disease Prevention: Focus on Old and New Drugs. Pharm 2018, Vol 6,
510		Page 10 2018; <b>6</b> :10. doi:10.3390/PHARMACY6010010
511	47	Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human
512		erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol
513		1991; <b>261</b> :E642–6. doi:10.1152/AJPENDO.1991.261.5.E642
514	48	Brier ME, Bunke CM, Lathon P V., et al. Erythropoietin-induced antinatriuresis mediated
515		by angiotensin II in perfused kidneys. J Am Soc Nephrol 1993;3:1583–90.
516		doi:10.1681/ASN.V391583
517	49	Masuda S, Kobayashi T, Chikuma M, et al. The oviduct produces erythropoietin in an

518 estrogen- and oxygen-dependent manner. Am J Physiol - Endocrinol Metab 519 2000;**278**:E1038–44. 520 doi:10.1152/AJPENDO.2000.278.6.E1038/ASSET/IMAGES/LARGE/AEND10610007X. 521 **JPEG** 522 50 Peng B, Kong G, Yang C, et al. Erythropoietin and its derivatives: from tissue protection 523 to immune regulation. Cell Death Dis 2020;11. doi:10.1038/S41419-020-2276-8 524 51 Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated 525 cardiovascular disease. Nat Rev Nephrol 2018 143 2018;14:185–201. 526 doi:10.1038/nrneph.2017.189 527 Joharapurkar AA, Pandya VB, Patel VJ, et al. Prolyl Hydroxylase Inhibitors: A 52 528 Breakthrough in the Therapy of Anemia Associated with Chronic Diseases. J. Med. Chem. 529 2018;**61**:6964–82. doi:10.1021/acs.jmedchem.7b01686 530 53 Sakashita M, Tanaka T, Nangaku M. Hypoxia-Inducible Factor-Prolyl Hydroxylase 531 Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. In: Contributions to 532 Nephrology. S. Karger AG 2019. 112–23. doi:10.1159/000496531 533 54 Northrup V, Perez LJ, Edgett BA, et al. Intron retention is a mechanism of erythropoietin 534 regulation in brain cell models. Gene 2024;898:148099. doi:10.1016/j.gene.2023.148099 535 55 Northrup V, Maybank A, Carson N, et al. The Value of Next-Generation Sequencing in 536 the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice. Am J Clin 537 Pathol 2020;153:639–45. doi:10.1093/AJCP/AQZ203 538 539 540

#### 541 **Tables** 542

543 544 545

546

547

# **Table 1 - Primers**

Target	Primer Name	Sequence 5'→3'
EPO rs507392	hEPO_1045F_M13	GTAAAACGACGGCCAGTGTGGCCC
		CAAACCATACCTG
	hEPO_1981R_M13	CAGGAAACAGCTATGACACTGACG
		GCTTTATCCACA
EPO rs551238	hEPO_2631F_M13	GTAAAACGACGGCCAGTCACCCTG
		CAAAATTTGATGCC
	hEPOdown677R_M13	CAGGAAACAGCTATGACAGTGACC
		CATGATTGCACC
EPO rs1617640	h_EPOpro1316F_M13	GTAAAACGACGGCCAGTAGTGCTG
		GGATTATAGGTGTCA
	h_EPOpro404_M13	CAGGAAACAGCTATGACAGAGATG
		CCTGGGTTGCTG
M13 sequencing	M13_F	GTAAAACGACGGCCAGT
	M13_R	CAGGAAACAGCTATGAC

# Table 2 - Cycling conditions for gDNA end-point PCR

1 able 2 - Cyclii	Table 2 - Cycling conditions for gDNA end-point i CK.											
Step	h_EPOpro1316F_M13,	hEPO_1045F_M13,	hEPO_2631F_M13,									
	h_EPOpro404R_M13	hEPO_1981R_M13	hEPOdown677R_M13									
Initial	10 min @ 95°C	10 min @ 95°C	10 min @ 95°C									
Denaturation												
Denaturation	30 sec @ 95°C	30 sec @ 95°C	30 sec @ 95°C									
Annealing	30 sec @ 58°C	30 sec @ 58°C	30 sec @ 58°C									
Extension	45 sec @ 72°C	60 sec @ 72°C	90 sec @ 72°C									
Cycles	35	35	35									
Final	10 min @ 72°C	10 min @ 72°C	10 min @ 72°C									
Extension												

Min=minutes, sec=seconds @=at

Table 3. Demographics of the OPOS sub-cohort

	Total	Anemia			Ι	<b>Dyslipidemia</b>		Hypertension			
	(n=95)	Cases (n=31)	Controls (n=64)	p-value	Cases (n=66)	Controls (n=29)	p-value	Cases (n=70)	Controls (n=25)	p-value	
Age (years)	$63.5 \pm 6.6$	$65.1 \pm 5.8$	$62.7 \pm 6.8$	0.5	$64.3 \pm 6.3$	$61.7 \pm 6.8$	0.03	$64.2 \pm 6.9$	$61.6 \pm 5.3$	0.04	
Females	30 (32%)	16 (52%)	14 (22%)		17 (26%)	13 (45%)		17 (24%)	13 (52%)		
BMI (kg/m <sup>2</sup> )	$31.8 \pm 7.3$	$34.4 \pm 9.4$	$30.5 \pm 5.6$	0.007	$31.3 \pm 6.0$	$32.7 \pm 9.6$	0.70	$31.4 \pm 6.3$	$32.8 \pm 9.6$	0.10	
Hemoglobin (g/L)	$134.8 \pm 14.7$	117.8 ±	142.6 ±	< 0.0001	134.8 ±	$135.0 \pm$	0.60	134.9 ±	$134.7 \pm$	0.82	
		11.5	7.8		14.6	14.8		15.2	12.9		
Hematocrit (L/L)	$0.40 \pm 0.04$	0.35 ± 0.03	$0.42 \pm 0.02$	< 0.0001	$0.40 \pm 0.04$	$0.40 \pm 0.04$	0.46	$0.40 \pm 0.04$	$0.40 \pm 0.03$	0.75	
MCV (fl)	90.1 ± 4.3	88.2 ± 4.7	90.9 ± 3.8	0.052	89.4 ± 4.2	91.9 ± 3.9	0.054	$90.3 \pm 4.3$	89.6 ± 4.2	0.55	
RBC $(x10^{12}/L)$	$4.4 \pm 0.4$	$4.0 \pm 0.4$	$4.6 \pm 0.3$	< 0.0001	$4.5 \pm 0.4$	$4.4 \pm 0.4$	0.81	$4.4 \pm 0.5$	$4.5\pm0.3$	0.53	
HbA1c (%)	$6.1 \pm 1.0$	$6.2 \pm 1.3$	$6.0 \pm 0.9$	0.68	$6.2 \pm 1.1$	$5.8 \pm 0.8$	0.29	$6.1 \pm 1.1$	$5.8 \pm 0.8$	0.42	
Cholesterol	$4.1\pm1.2$	$4.0 \pm 1.1$	$4.1 \pm 1.2$	0.86	$3.9 \pm 1.1$	$4.5\pm1.1$	0.06	$3.9 \pm 1.2$	$4.4\pm1.1$	0.52	
(mmol/L)											
HDL (mmol/L)	$1.2 \pm 0.4$	$1.2 \pm 0.4$	$1.2 \pm 0.3$	0.66	$1.2 \pm 0.3$	$1.4 \pm 0.3$	0.057	$1.2 \pm 0.4$	$1.3 \pm 0.3$	0.26	
LDL (mmol/L)	$2.1 \pm 0.9$	$2.1 \pm 0.9$	$2.1 \pm 0.9$	0.89	$2.0 \pm 0.8$	$2.5 \pm 1.0$	0.03	$2.0 \pm 0.9$	$2.5 \pm 1.0$	0.51	
LDL/HDL	$1.8 \pm 0.8$	$1.7 \pm 0.8$	$1.8 \pm 0.7$	0.63	$1.7 \pm 0.7$	$1.9 \pm 0.7$	0.38	$1.7 \pm 0.7$	$1.9 \pm 0.8$	0.92	
Non-HDL (mmol/L)	$2.9 \pm 1.1$	$2.8 \pm 1.0$	$2.9 \pm 1.1$	0.75	$2.7 \pm 1.1$	$3.1\pm1.0$	0.17	$2.8 \pm 1.1$	$3.1\pm1.0$	0.79	
Triglycerides	$1.6 \pm 1.1$	$1.8 \pm 1.2$	$1.6 \pm 1.0$	0.58	$1.7 \pm 1.2$	$1.3\pm0.6$	0.27	$1.7 \pm 1.2$	$1.4 \pm 0.6$	0.59	
(mmol/L)											
NLR	$3.9 \pm 5.1$	$6.1 \pm 8.5$	$2.9 \pm 1.2$	0.11	$3.8 \pm 4.6$	$4.1 \pm 6.0$	0.47	$4.2 \pm 5.7$	$3.1 \pm 2.1$	0.55	

BMI=Body mass index, HDL=high-density lipoprotein, LDL=low-density lipoprotein, MCV=Mean Corpuscular Volume, RBC=red blood cells (erythrocytes), NLR=Neutrophiles Lymphocytes ratio. p-value for continuous variable (BMI, Hemoglobin, Hematocrit, HbA1c, Cholesterol, HDL, LDL, MCV, Triglycerides, RBC, NLR) expressed as mean ±SD, p-value calculated using t-test. Categorical variable (Sex) expressed as number of cases (percentage of group), p-value calculated using Chi-square test. Significant p-value of <0.05 are bolded.

Table 4. Association of anemia, dyslipidemia and hypertension by genotype

		Anei	nia			Dyslipi	demia				Hy	pertension
	Cases	Control	OR	P-	Cases	Control	OR	P-	Cases	Control	OR	P-value
			(95%	value			(95%	value			(95%	
			CI)				CI)				CI)	
	rs1617640											
AA	8	30	2.83	0.065	29	9	0.41	0.11	28	10	1.24	0.73
AC	11	21	(0.93-		23	9	(0.14-		24	8	(0.36-	
CC	12	12	8.60)		13	11	1.23)		18	6	4.29)	
A	27	81	1.96	0.04	81	27	0.64	0.15	80	28	1.24	0.54
$\overline{\mathbf{C}}$	35	45	(1.02-		49	31	(0.34-		60	20		
			<b>3.79</b> )				1.19)				(0.62-	
											2.48)	
							r	s507392	2			
AA	7	29	2.58	0.12	28	8	0.29	0.048	27	9	1.21	0.79
AG	8	23	(0.78-		23	8	(0.09-		25	6		
GG	8	11	8.55)		10	9	1.00)		15	4	(0.29-	
•			1.50	0.10	<b></b>	2.1	0.50	0.055	<b>7</b> 0		4.94)	0.71
A	22	81	1.73	0.12		24	0.53	0.066	79	24	1.29	0.51
G	24	45	(0.86-		43	26	(0.27-		55	14	(0.60-	
			3.46)				1.05)	s551238	<b>)</b>		2.81)	
тт	0	22	2 22	0.19	20	10				11	1 01	0.42
TT	8	32	2.32	0.18	30	10	0.26	0.11	29	11	1.81	0.43
TG	9	22	(0.68-		23	8	(0.11-		24	7	(0.39- 8.30)	
GG	7	10	7.97)		9	8	1.27)		14	3	· · · · · · · · · · · · · · · · · · ·	
T	25	86	1.63	0.17	83	28	0.66	0.23	82	29	1.55	0.27
G	23	42	(0.81-		41	24	(0.33-		52	13	(0. <b>-</b> 0	
			3.25)				1.30)				(0.70-	
		. Cl-confid									3.40)	

OR=Odds Ratio, Cl=confidence limit

**Table 5. Haplotype association** 


Haplotype		Anemia			Dyslipidemia	Hypertension				
	Frequency	OR (95% CI)	p-value	Frequency	OR (95% CI)	p-value	Frequency	OR (95% CI)	p-value	
AAT	0.5674	1.00	n/a	0.5673	1.00	n/a	0.5672	1.00	n/a	
CGG	0.3837	1.98 (1.01-3.91)	0.051	0.3848	0.72 (0.36-1.44)	0.36	0.3836	1.45 (0.69-3.05)	0.33	
CGT	0.0311	3.05 (0.38-24.72)	0.3	0.0298	0.05 (0.00-0.51)	0.014	0.329	0.39 (0.05-2.99)	0.37	
GHA p- value		0.19			0.031			0.36		

OR=Odds ratio, Cl=confidence limit, GHA=global haplotype association, n/a=not applicable

Table 6. Sex differences

				Anemia				Dyslipidemia				Hypertension	
Sex	Gen. Case Ctrl OR (95% CI) Int.		Int.	Case	Ctr	OR (95% CI)	Int.	Case	Ctr	OR (95% CI)	Int.		
						rs1	61764	0					
F	A/A	4	5	1.00	0.99	5	4	1.00	0.5	3	5	1.00	0.1
	A/C	6	6	1.69 (0.25-11.25)	_	8	4	2.19 (0.33-14.68)	-	8	2	9.38 (0.90-98.15)	-
	C/C	6	3	4.03 (0.45-35.91)	-	4	5	0.82 (0.11-6.28)	-	4	2	6.48 (0.47-89.67)	-
M	A/A	4	25	1.00	_	24	5	1.00	-	24	5	1.00	-
	A/C	5	15	1.82 (0.39-8.43)	_	15	5	0.55 (0.13-2.33)	-	16	4	0.50 (0.10-2.55)	-
	C/C	6	9	3.80 (0.79-18.35)	_	9	6	0.27 (0.06-1.27)	-	12	2	0.54 (0.07-4.09)	-
						rs	507392	2					
F	A/A	3	4	1.00	0.65	4	3	1.00	0.65	2	5	1.00	0.03
	A/G	3	7	0.73 (0.08-6.54)	-	7	3	1.88 (0.21-16.79)	-	8	2	18.48 (1.50-227.27)	-
	G/G	4	3	3.55 (0.31-40.81)	_	3	4	0.43 (0.04-5.13)	-	5	2	15.43 (1.02-233.40)	-
M	A/G	4	25	1.00	-	24	5	1.00	-	25	4	1.00	-
	G/G	5	16	1.89 (0.41-8.82)	-	16	5	0.55 (0.13-2.33)	-	17	4	0.51 (0.10-2.63)	-
	C/C	4	8	2.78 (0.51-15.09)	_	7	5	0.21 (0.04-1.11)	-	10	2	0.45 (0.06-3.49)	-
						rs	551238	3					
F	T/T	4	4	1.00	0.57	4	4	1.00	0.42	2	6	1.00	0.02
	T/G	4	7	0.59 (0.08-4.36)	_	8	3	3.22 (0.40-25.64)	-	9	2	19.16 (1.84-199.49)	-
	G/G	3	3	1.80 (0.17-19.69)	_	2	4	0.55 (0.05-6.61)	-	4	2	11.33 (0.84-153.49)	-
M	T/T	4	28	1.00	_	26	6	1.00	-	27	5	1.00	-
	T/G	5	15	2.26 (0.48-10.58)	-	15	5	0.62 (0.15-2.52)	-	15	5	0.47 (0.11-2.06)	-
	G/G	4	7	3.40 (0.61-18.82)	-	7	4	0.32 (0.06-1.72)	-	10	1	1.11 (0.10-12.27)	-

F=female, M=male, Geno=Genotype, Ctrl=Control, OR=odds ratio, Int=Interaction p-value, Cl=confidence limit



**Figure 1. Plasma EPO concentration is decreased in rs161640 CC genotype and rs507392 GG genotype, but not rs51238.** Transferrin and Hepcidin showed no genotype correlation although there does appear to be variation in Ferritin it does not reach significance. Plasma concentrations were determined using ELISA assays with outliers marked by circles and excluded from statistical analysis. Outliers were determined by ROUT test and *a priori* as two standard deviations from the mean or else being below the lower limit of detection of the ELISA. ANOVA was used to determine significance with p-values < 0.05 deemed significant.